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Background: Approximately 20% of adult cancer patients are eligible to participate in a clinical trial, but only 2.5-9%
do so. Accrual is even less for minority and medically underserved populations. As a result, critical life-saving treatments
and quality of life services developed from research studies may not address their needs. This study questions the utility
of the bioethical concern with therapeutic misconception (TM), a misconception that occurs when research subjects fail
to distinguish between clinical research and ordinary treatment, and therefore attribute therapeutic intent to
research procedures in the safety net setting. This paper provides ethnographic insight into the ways in which
research is discussed and related to standard treatment.
Methods: In the course of two years of ethnographic fieldwork in a safety net hospital, I conducted clinic observations
(n = 150 clinic days) and in-depth in-person qualitative interviews with patients (n = 37) and providers (n = 15). I used
standard qualitative methods to organize and code resulting fieldnote and interview data.
Results: Findings suggest that TM is limited in relevance for the interdisciplinary context of cancer clinical trial
recruitment in the safety net setting. Ethnographic data show the value of the discussions that happen prior to
the informed consent, those that introduce the idea of participation in research. These preliminary discussions are
elemental especially when recruiting underserved and vulnerable patients for clinical trial participation who are
often unfamiliar with medical research and how it relates to medical care. Data also highlight the multiple actors
involved in research discussions and the ethics of social justice and patient advocacy they mobilize, suggesting
that class, inequality, and dependency influence the forms of ethical engagements in public hospital settings.
Conclusion: On the ground ethics of social justice and patient advocacy are more relevant than TM as guiding
ethical principles in the context of ongoing cancer disparities and efforts to diversify clinical trial participation.Background
In 1993 the National Institutes of Health passed the
NIH Inclusion Act, designed to address the overwhelm-
ing reliance on white middle class men for pharmaceut-
ical drug development. Although immediately concerned
with the generalizability of treatments, policy changes
subsequent to the Inclusion Act presume that participa-
tion in clinical trials “produces therapeutic benefits that
should be accessible to all” [1,2]. Since this time, a pro-
liferation of research into the how, why, and why not of
clinical trial participation and recruitment has led toCorrespondence: nburke@cc.ucsf.edu
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unless otherwise stated.what Steven Epstein has characterized as a new field of
study: recruitment science or recruitmentology [3]. Gen-
erally structured according to ethnically defined differ-
ences in attitudes toward research–including barriers
such as historically-based mistrust in the healthcare sys-
tem, fears of experimentation, and misunderstandings of
scientific methods such as randomization–the recruit-
mentology literature largely misses, or obfuscates, class
and access issues as bases for low participation rates [4].
Importantly, this literature focuses on increasing par-
ticipation of minority individuals in trials taking place in
academic medical centers, more than pharmaceutical in-
dustry sponsored trials in private practices and contract
research organizations (CROs). This is due to a shift that
occurred in the structure of US clinical trials in theis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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replaced universities in pharmaceutical contracts from
more than 80% in the academy prior to 1990 to less than
35% in 2005 [5-7]. Adriana Petryna [8,9], Jill Fisher [6,10],
Roberto Abadie [11] and others have chronicled the im-
pact CROs and their effective recruitment strategies have
had on underserved and drug naïve populations in the
United States and globally. This research has shown that
participation in clinical trials taking place in low resource
settings often provides the only access available to profes-
sional medical care in dilapidated and substandard health-
care systems.
In the United States academic medical centers often
serve as both the “safety net” for poor and medically
underserved individuals and as sites for innovative med-
ical research. While definitions of safety net institutions
vary, the Institute of Medicine’s 2000 report America’s
Health Care Safety Net: Intact But Endangered defines
“core safety net providers” as those institutions who offer
patients access to services regardless of their ability to pay
and serve a “substantial share” of uninsured, Medicaid,
and other vulnerable patients [12]. In those safety net in-
stitutions also serving as teaching and research sites, fac-
ulty and providers often receive research funding from the
National Institutes of Health or other federal agencies.
Since the passage of the NIH Inclusion Act in 1993, all
such funded research has been required to actively recruit
and include women and minorities. Despite this, under-
served cancer patients are typically offered fewer oppor-
tunities to participate in research than other patients and
recruitment of minority participants remains a substantial
challenge [13-16]. As a result, critical life-saving treat-
ments and quality of life services developed from research
studies may not address their needs. Therefore, it is im-
portant to understand what actually happens when com-
plex cancer clinical trials are discussed with medically
underserved and ethnic minority patients in safety net
settings.
Parallel but not intersecting with these shifts in the
structure and implementation of US scientific research in
the in the 1990s has been the emergence of the concern
with and study of therapeutic misconception (TM) among
bioethicists. Defined as “when a research subject fails to
appreciate the distinction between the imperatives of
clinical research and of ordinary treatment, and there-
fore inaccurately attributes therapeutic intent to re-
search procedures,” [17,18] therapeutic misconception
concerns the conflation of research and medical care. Ac-
cording to the definition of TM, true informed consent,
and therefore ethical participation, is only possible if pa-
tients understand the differing intentions–and roles–of re-
search and medical care staff. Importantly, TM is often
studied as a phenomenon among white, middle class, in-
sured populations [17-19]. In addition, the informedconsent described in the TM literature is largely limited to
discussion of the elements of the informed consent form.
Such discussions focus on the risks and benefits of re-
search participation, experimental procedures in the
protocol, and the rights of research participants. Not
considered in the TM literature are the discussions that
happen prior to the informed consent, those that introduce
the idea of participation in research. As this paper explores,
these preliminary discussions are elemental especially when
recruiting underserved and vulnerable patients for clinical
trial participation who are often unfamiliar with medical
research and how it relates to medical care.
Considerations of health literacy suggest a different
way to approach therapeutic misconception as a risk to
ethical conduct of research recruitment. The World
Health Organization (WHO) Commission on the Social
Determinants of Health (2007) defines health literacy
as “the cognitive and social skills which determine the
motivation and ability of individuals to gain access to,
understand, and use information in ways which pro-
mote and maintain good health” [20]. Being informed
in the manner envisioned by bioethicists concerned
with TM involves skills and competencies that relate
both to the information itself and to the medium
used to access that information [21]. Health literacy
has recently been linked to the ethical debate regard-
ing equitable access to research in the concept of
‘research literacy,’ “the cognitive and social under-
standing of the basic purpose, process, and value of re-
search and research participation” [22]. Research literacy,
as currently conceptualized, depends upon information
and education to address therapeutic misconception [22].
The ethnographic data presented in this paper suggests
that considerations of the entire clinical trial communica-
tion process, including the initial introduction of the idea
of participation in research, should be considered elemen-
tal opportunities for addressing (and perhaps assessing)
research literacy.
Understanding the different roles of research and med-
ical care staff is especially difficult when the therapeutic
and research roles are embodied in the same person, and
when this person is the gatekeeper to research parti-
cipation. Little research has considered the relevance of
bioethical concerns about therapeutic misconception to
clinical trials recruitment of minority and medically under-
served patients. Based in ethnographic observations of clin-
ical trial discussions in public hospital oncology clinics, this
study questions the saliency of the therapeutic misconcep-
tion concept in the recruitment of medically underserved
cancer patients for participation in clinical research, and
suggests that the on the ground ethical logics of social just-
ice and patient advocacy may be more useful for under-
standing the perspectives and communicative strategies of
differently positioned individuals in the clinic.
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of a study of information disparities in cancer clinical trial
recruitment in safety net settings. Framed as a case study,
the paper includes in-depth ethnographic description of a
cancer clinical trials recruitment discussion to 1) elucidate
the ethics employed in clinical trials discussions; 2) de-
scribe multiple competing perspectives on appropriate
communication; and 3) demonstrate how and when the
informed consent process actually begins, and how elem-
ental these preliminary discussions are to patient under-
standing and acceptance of research participation.
Methods
This paper draws upon ethnographic research conducted
in safety net hospital oncology clinics over the course of
two years during which I conducted in-depth interviews
with 37 oncology patients in either English or Spanish and
with 15 providers (oncologists, surgeons, fellows, resi-
dents, patient navigators, social workers, and nurse practi-
tioners). I systematically observed over 150 clinic days, the
details of which I recorded in field notes. All participants
in the study provided informed consent (verbal during ob-
servations; written during interviews). All study proce-
dures were reviewed and approved by the University of
California, San Francisco Committee on Human Research.
The combination of interviews and observations pro-
vided a complex rendering of the range of experiences of,
and communications around, cancer care and clinical trial
recruitment. Observations took place in two outpatient
oncology clinics in a Northern California safety net hos-
pital from 2008 to 2010. All patients and providers in the
clinics were considered eligible for participation. At the
beginning of each clinic day, I asked a resident, fellow, or
oncologist if I could shadow him/her during clinic and
record my observations in a small notebook I kept with
me. Throughout the clinic day I followed these providers
into the spaces where cases were presented to attendings,
pathology reports discussed, eligibility determined, and
treatment plans outlined. Prior to each patient visit, I
approached the patient and asked if s/he minded if I ob-
served the visit, ensuring her/him in accordance with a
verbal consent script approved by the University Commit-
tee on Human Subjects Research that refusing to do so
would in no way influence the care given. In the course of
two years, one patient asked that I not be present due to
the presence of her two sisters and the small size of the
examination room. Because these clinics took place in a
teaching hospital, it was common to have a number of
people in the exam room, often times taking notes. There-
fore the addition of the anthropologist was less disruptive
than it may have been in a different care setting. I asked
all patients who were offered participation a clinical trial
to participate in an in-person, in-depth interview at a time
and place convenient for them. Interview participantssigned an informed consent document (translated to
Spanish for those who preferred to be interviewed in
Spanish) and were given a $30 incentive in appreciation of
their time.
In addition to clinic observations and interviews, I
attended patient education/support groups, grand rounds,
pre-clinic staff meetings, and tumor boards. I used stand-
ard qualitative methods, including member checking, to
organize and code resulting interview and field note text
[23] in order to develop a thematic understanding of on-
cology practice, clinical trial recruitment communications,
and patient experience in the clinics [24]. The findings re-
ported here draw primarily from observations recorded in
field notes, but are informed by insights gained through
detailed coding and analysis of all interview and field note
data.
The research setting
Scheduling practices and flow differed substantially be-
tween the two clinics in which I worked but both were
time-pressured environments with overworked and very
committed staff. At times the atmospheres were chaotic
with people rushing from place to place, addressing mul-
tiple emergencies at once. At others there were lulls dur-
ing which providers discussed having attended a patient’s
funeral over the weekend, or having checked in on a re-
cently admitted patient whose cancer treatment had
caused complications, generally expressing their care and
concern for patients beyond the clinic.
In the general oncology clinic, patients were assigned
a consistent provider, usually an oncology fellow, for up
to six months, at which point fellows rotated out of the
clinic. Patients received a specific appointment date and
time linked to their provider’s schedule. Despite this, pa-
tients waited one to four hours in the clinic waiting
room. The hallways were often filled with patients wait-
ing to have their lab tests taken and to meet with social
workers. Research assistants recruiting for various pro-
jects also clogged the hallways. Staff pulled chairs out of
exam rooms for older patients suffering the effects of
chemotherapy to sit in, especially those uncomfortable
with the smells and discussions occurring in the over
crowded waiting room. The walls in the hallways were
adorned with black and white photographs of cancer pa-
tients, some recently deceased, who had participated in
the hospital’s support group program.
The interdisciplinary breast clinic was held in another
part of the hospital one afternoon a week. Unlike the gen-
eral oncology clinic, patients were scheduled in blocks in
breast clinic, resulting in waiting rooms that filled at the
beginning and midway through the afternoon, and wait
times were similar to those of the general oncology clinic:
between one and four hours. Unlike the general oncology
clinic, the breast clinic walls were painted an off white and
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vacations. Chairs were not allowed in the hallway and pa-
tient navigators (bilingual staff providing informational
and practical support to guide patients through interdis-
ciplinary breast cancer treatment), medical interpreters,
the clinical trials coordinator, and researchers leaned
against walls waiting for appointments and patient ar-
rivals. Patients never knew which provider they would see
in this clinic, unlike the general oncology clinic. Their
charts were stacked in order of appointment on a table in
the middle of a long hallway. During clinic providers
picked up the top chart and reviewed it quickly before go-
ing in to see the patient. If the patient was eligible, or
thought to be eligible, for a clinical trial, the clinical trials
coordinator (CRC) would put a bright sticky note on the
chart asking the provider to talk with the coordinator be-
fore going in to see the patient. Busy surgeons and stu-
dents and residents rotating through the clinic often
avoided these charts and instead selected the next in line.
Those who did pick up the charts with a sticky note re-
ceived a quick description of the trial from the CRC in the
hallway outside the exam room while patients and pro-
viders streamed by. The provider was tasked with remem-
bering, from this quick description in the hallway, the
basics of the trial enough to describe it to the patient prior
to inviting the CRC in to administer informed consent.
Breast and general oncology clinic patients range in age,
ethnicity, and educational background. The safety net hos-
pital within which these clinics reside serves a diverse pa-
tient population of 2.5 million patients a year, 29% of
whom are Latino. Patients at this hospital speak approxi-
mately 20 different languages. About 80% of the total
population that the hospital serves receives publicly funded
health insurance (Medicare or Medi-Cal) or is uninsured.
Importantly, cancer patients in this safety net hospital tend
to be younger, have multiple co-morbidities including sub-
stance abuse and mental health issues, and many are non-
English speakers or Low English Proficient.
Results
Interviews revealed that patients often did not remember
being offered participation in a clinical trial. All treatment
discussions, whether experimental or standard, seemed to
stream together in their minds as they recounted struggles
to keep up with information, appointments, bills, families
and jobs. Patients at this safety net hospital generally, and
hence many interviewees, lived in single occupancy hotels
or other substandard housing, lacked health insurance,
often spoke little English, and were usually grateful for the
care they had received since their diagnosis. Many
recounted financial difficulties including the need to pay
rent, hold down a job while managing appointment sched-
uling and exhaustion from therapy, and pressure to send
remittances to family in countries of origin. Stressstemming from unstable living situations and multiple
family responsibilities including parenting challenges were
also common themes. In light of these many competing
priorities, the expectation that patients acquire the spe-
cialist knowledge necessary to recount and make as-
sessments of research versus treatment, the basis for
informed consent to participate in research, was par-
ticularly challenging.
One of the oncologists in the clinic (Dr. Lee)a staunchly
believed this, and invoked a social justice ethic of inclu-
sion and research access to explain her approach to clin-
ical trial recruitment. She stated, “It’s a matter of justice.
We need patients like ours represented in these studies.
It’s our job to make sure they know about studies and
how important it is for them to participate.” In response
to my comment that few patients interviewed remem-
bered being offered a trial, she said, “ah, that means we’re
doing our job.” In other words, clinic providers were mak-
ing research participation a normal part of cancer care.
Dr. Lee expressed her strong belief that clinic patients
should be represented in the production of evidence and
treatment innovation to new oncology fellows when they
rotated onto the service. She also discussed the import-
ance of clear communication about clinical trials and the
need to be aware of differing literacy levels and cultural
orientations. When discussing research participation with
breast cancer patients, she explained that the way we
know how to provide treatment is because other women
participated in early studies, thus invoking a ‘public good’
or ‘gift to other women’ rationale.
In the following I describe a consultation this oncologist
had with a monolingual Spanish-speaking patient regarding
clinical trial participation. The excerpt, similar to other trial
recruitment discussions I observed, highlights challenges to
clear communication, differing perspectives on appropriate
information, and struggles to both conflate and distinguish
research and care. It also highlights the role of actors not
present in bioethical debates about therapeutic misconcep-
tion–but present in the care of underserved patients–and
their potential influences on clinical trial recruitment and
decision-making. In this safety net hospital, additional influ-
ential actors include medical interpreters and patient navi-
gators. Lastly, this field note excerpt illustrates the
importance of expanding notions of ethical consent beyond
discussion of the consent form to the initial introduction of
the possibility of research participation.
Ethnographic Field note
It was a busy day in clinic. There were few providers –
an expected Fellow failed to arrive – and a stack of
charts with patients waiting in the waiting room. Dr.
Lee, seated at a desk in the middle of the hallway,
discussed Millie’s chart with the resident who had
Burke BMC Medical Ethics 2014, 15:68 Page 5 of 7
http://www.biomedcentral.com/1472-6939/15/68been in to see her to determine if she was eligible for
an ongoing chemotherapy trial. Since this was a
teaching clinic, small exam rooms often
accommodated students and attending physicians as
well as patients and, sometimes, family members or
patient navigators. This crowd sometimes increased
when trials were to be discussed, contributing a feeling
of gravitas to the discussion. In this case, Millie and
her brother watched as Dr. Lee, the navigator, the
clinical trials coordinator, the resident, and the
anthropologist all filed in.
Dr. Lee started off explaining that Millie needed to
start chemotherapy. She then said that one of the
things she wanted to talk about with Millie was the
possibility of participating in a study on how best to
give chemotherapy. Dr. Lee explained that one of the
ways they can find out the best way to give
chemotherapy is by asking women with breast cancer
to help them figure it out. Millie asked, “What do they
do in those studies?” The navigator interpreted as Dr.
Lee explained that this particular study was a
chemotherapy study that looks at a couple of old
drugs, plus one new drug; half of the women get the
“regular stuff” and the other half get the additional
knew drug. The navigator stopped interpreting, turned
to Dr. Lee and asked, “Is this a randomized trial”? Dr.
Lee turned to the navigator and responded “yes.” The
navigator translated this response as “we wouldn’t
know if you…which one you would get because it is
basically a lottery.” Dr. Lee turned to the navigator
and asked, “How did you say that exactly?” Her tone
indicated annoyance despite the smile on her face. The
resident, who also spoke Spanish, answered that the
navigator had said, “It is basically a lottery.” “The
point is,” Dr. Lee said, “You don’t decide, I don’t
decide. The computer decides who gets which; that’s in
order for it to be completely fair.” The resident
translated this response. Millie then asked “But the
two medicines that they gave before worked?” The
resident translated again. Dr. Lee answered “yes.”
Millie started to ask a question regarding the number
of medications she would receive. Dr. Lee interrupted,
saying that the new medication also works, because it
has been tested in women with breast cancer before.
The navigator interpreted, saying, “It would only be
three medications, two are the normal medication plus
the new medication which they have tested by itself
and it has proven to work, but they want to know if it
works best…” Dr. Lee said, “We haven’t described the
trial quite correctly, but that’s okay,” to which the
navigator responded that Millie was asking if she wasgoing to get the two plus three more medications. Dr.
Lee said no, that the medication in both cases were
known to work, and one of the questions they have is
which one works better. The navigator responded that
she was trying to explain that to Millie, but Millie
wanted to know if she would receive more than three
medications, to which Dr. Lee responded “no.” The
navigator interpreted, “It will always be the two that
they offered before.” The doctor said, “That is the part
where you are not quite right, but that’s okay.” The
navigator asked for clarification, to which Dr. Lee
responded that it was not important to explain it;
what was important was to say that in both cases the
medicines are known to work and the only question is
which one works better than the other. Dr. Lee said,
“don’t discuss the numbers.” The navigator responded,
“but she wants to know the number, if there are going
to be three or five medications.” “There are no more
than three,” Dr. Lee said.
Millie asked “The two that work, they add one more,
isn’t that too strong for the person?” Dr. Lee answered,
“It is not about muy fuerte” and added that the
secondary effects are different, but about the same.
Millie asked, “When they give three medicines, is the
dose less?” The resident again interjected, stating that
the doses have been established in previous parts of
the experiment. The navigator responded, but “she
wanted to know if she is going to get the same number
of doses,” to which Dr. Lee responded that this was
more detail than was necessary at this point; what
they really wanted to ask was if Millie would think
about the possibility of being part of the study, and
that the details would be explained later if she
decided to do it. The question was about the principle
of whether or not she would be interested in being part
of a research study.
Discussion
The competing logics of clinical trial recruitment and im-
mediate concerns and needs [25] cause a rupture in man-
agement of the discussion in my field notes. Whereas
Millie was focused on immediate bodily therapeutic con-
cerns (numbers of drugs, intensity of dosages, and variabil-
ity of side effects), Dr. Lee asked her to push these
concerns aside to consider the abstract idea of participating
in research. The consideration of research participation,
therefore, was taken somewhat out of the treatment con-
text, despite Dr. Lee’s desire to manage research as a nor-
mative part of treatment. The confusion inherent in these
competing logics became clear later in the conversation
when Millie seemed to come to an understanding of the
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and stated, “so I don’t need to make a decision.” Assured
by the navigator that she actually did need to, Millie reas-
serted her need to know “all the details” before doing so.
Some argue that the lack of improvement in terms of de-
creasing mortality due to cancer since the institution of
Nixon’s “War on Cancer” over 40 years ago is due to the
low participation rate–variably reported as 2 to 9% - of eli-
gible adult oncology patients in studies of cancer treat-
ments. A 2010 JAMA commentary noted that the 2010
Institute of Medicine Report (Transforming Clinical Re-
search in the United States) and initiatives such as the
Clinical Trials Transformation Initiative “recognize that
successful recruitment and retention of participants in clin-
ical trials is critical for improving the efficiency and effect-
iveness of phase III and IV clinical trials and that action to
ensure adequate enrollment is urgently needed” [26]. The
authors go on to state that “the importance of health care
professionals as gatekeepers for clinical trial participation
cannot be overstated” [26].
The question of who is considered a gatekeeper in clin-
ical trials recruitment is an important one raised in my re-
search. In much of the bioethics and public health
literature on informed consent and ethical participation in
research, the “problem” is framed as lack of clarity in infor-
mation, rather than equity in collaboration or access. “In-
formation,” in this sense, is understood as a necessary
precursor to the development of new partnership and
shared decision-making relationships between healthcare
practitioners and patients [21]. However, this model of pa-
tient education tends to assume a binary exchange between
provider and patient, without accounting for the presence
of others who might introduce competing ethics and un-
derstandings based in patient advocacy into the discussion.
By introducing the concept of randomization into Dr. Lee’s
presentation of the research design, the patient navigator
signaled an essential difference between the clinical trial
and standard care. She also advocated her own version of
social justice by influencing the direction of the conversa-
tion toward clarifying and discussing these differences, ra-
ther than directly interpreting what was being said.
Elsewhere, I have discussed the challenges evident in this
communication as clinic “noise” [27]. In other words, pro-
viders may receive patient questions about treatment,
doses, and bodily effects as obstructive “noise” complicat-
ing the clinical trial discussion, while patients perceive
these same questions as essential information needs stem-
ming from concerns about time away from work, energy
for parenting, and other living conditions. Patients, in
this shared-decision-making framework, are tasked
with understanding the differences between the scien-
tific model of research and medical care, with relatively
little, even sometimes conflicting, guidance on how to do
that. If unable to do so, they suffer from misconception. Inthis model potential research participants are produced as
bearers of both rights and responsibilities. They have enti-
tlements to disclosure, but obligations to assess the infor-
mation they are given carefully, to understand, to make
rational decisions, and to avoid false hope or expectations
[28]. Clinicians, too, emerge as having rights and responsi-
bilities. They have the right to solicit agreement and study
participation from their patients and also the responsibil-
ities to ensure patients continue to receive proper thera-
peutic care, to discuss clearly and completely when and
why treatment and research protocols deviate, and to
avoid inducing false hopes or expectations. Importantly,
the discussion in my field note, like many I observed,
took place prior to the discussion usually considered in
ethical analyses of clinical trial recruitment. One could
argue that this field note records a discussion of assent
to discuss the possibility of participating, and therefore
is not subject to the concerns raised by bioethicists re-
garding therapeutic misconception. At the same time,
this field note demonstrates how and when the informed
consent process actually begins, and how elemental these
preliminary discussions are to patient understanding and
acceptance of research.
Hallowel and colleagues [29] suggest the problem of
ethical consent to research participation is the result of
the desire to dichotomize and classify what are intrinsic-
ally hybrid activities (i.e. activities that might have scien-
tific intent but therapeutic benefit) into either care or
research [29]. Rather, they suggest a focus on what is go-
ing to happen, rather than the why [29]. As the conver-
sation between Millie, the navigator, the resident, and
Dr. Lee illustrates, slippage between explaining the what
and the why of research may cause confusion, tension,
and possible mistrust of research. In this case, Millie de-
cided not to participate.
Limitations
As an inductive, ethnographic study, this research is lim-
ited to a recounting of phenomena that occurred at a spe-
cific time and in a specific context. While data presented
provide insights into communication processes likely rele-
vant to other public hospital settings, the observations
were limited to two oncology clinics in one safety net hos-
pital and therefore are not generalizable.
Conclusions
Bioethicists promote the “ideal clinical trial participant
as an autonomous rational volunteer who is active in the
consumption of information about his or her health, has
options for care outside clinical research, and is able to
differentiate and choose among these options given his
or her personal health needs” [30]. In other words, the
onus is on the patient to comprehend biomedicine ra-
ther than on the clinician researcher to understand
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constrain patient interactions with the healthcare system
and their treatment decision-making. As one prominent
bioethicist, and original author of the ‘therapeutic mis-
conception’ paper stated, “most clinical trial participants
are middle class people with insurance,” [19] thus signify-
ing the class and resources presumed in therapeutic mis-
conception debates. These debates and concerns about
persistent therapeutic misconception have strongly in-
fluenced the shape of the current bioethics regulatory
system in the United States, embodied in local IRBs,
the National Bioethics Advisory Commission (NBAC),
federal mandates, and the US Common Rule (45 CFR46).
The continuing relevance of the ethical principal of
therapeutic misconception for shaping the participation
of the increasingly diverse and largely under-insured US
populations in clinical research, however, is not clear.
As evidenced in recruitment discussions in my research
site, the emergence of other ethical principles on the
ground, such as those concerned with social justice and
patient advocacy, suggest that class, inequality, and de-
pendency influence the forms of ethical engagements in
public hospital settings.
Endnote
aAll names have been changed to protect the anonym-
ity of participants.
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